A phase II biomarker assessment of tivozanib in oncology (BATON) trial in patients (pts) with advanced renal cell carcinoma (RCC).

TPS4686 Background: Tivozanib is an oral, potent, and selective tyrosine kinase inhibitor targeting all three vascular endothelial growth factor (VEGF) receptors; it showed efficacy and tolerabilit...